# US 2015/0104495 A1 · Compositions and methods for transdermal delivery of amphetamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104495 A1
- Document ID: US20150104495A1
- Status: Published application
- Kind: A1
- Application number: 14/577,028
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2012-10-25
- Assignees: Noven Pharmaceuticals, Inc.
- Inventors: Viet Nguyen; Steven DINH; Jun LlAO; Robert L. LAMBERT
- Web page: https://patentgrep.com/patent/US20150104495A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/703: {characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system stimulation, such as for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), or for the treatment of narcolepsy. In some embodiments, the compositions comprise an amount of polyurethane effective to control the presence of and/or prevent the formation of phenyl acetone in the compositions. The polyurethane may be present in a drug-containing polymer matrix or in a backing adjacent the drug-containing polymer matrix.

## Claims

### Claim 1

A composition for the transdermal delivery of amphetamine in the form of a flexible finite system for topical application, comprising a polymer matrix comprising a polymer and amphetamine or a pharmaceutically acceptable salt or prodrug thereof, wherein the composition comprises polyurethane in an amount effective to control the presence of and/or prevent the formation of phenyl acetone in the polymer matrix.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amphetamine includes amphetamine free base.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the polyurethane is a reaction product of an isocyanate and a polyol.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the polyurethane is a reaction product of (i) an isocyanate selected from the group consisting of diphenylmethane diisocyanate, toluene diisocyanate, p-phenylene diisocyanate, naphthalene diisocyanate, hexamethylene diisocyanate, isophorone diisocyanate, dicyclohexylmethane-4,4′-diisocyanate, meta-tetramethylxylylene diisocyanate and transcyclohexane diisocyanate and (ii) a polyol.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the polyol is a momomeric polyol.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the momomeric polyol is selected from the group consisting of glycerin, ethylene glycol, pentaerythritol, and sucrose.

### Claim 7 (depends on 4)

The composition of claim 4, wherein the polyol is a polymeric polyol.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the polymeric polyol is selected from the group consisting of natural oil polyols, polyols obtained by polymerization of diols and dicarboxylic acids, polyether polyols, polyols obtained from reacting glycerin with propylene oxide or ethylene oxide or a combination thereof, polycarbonate polyols, polycaprolactone polyols, polybutadiene polyols, and polysulfide polyols.

### Claim 9 (depends on 4)

The composition of claim 4, wherein the polyol is a combination of a monomeric polyol and a polymeric polyol.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition includes an amount of polyurethane from about 1/100 to about 100 times the amount of amphetamine in the composition.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the polymer matrix comprises polyurethane.

### Claim 12 (depends on 1)

The composition of claim 1, further comprising a backing.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the backing comprises polyurethane.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the backing comprises a polyurethane film layer adjacent the polymer matrix.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the backing comprises a layer adjacent the polymer matrix comprising a polyurethane fiber, particle or powder.

### Claim 16 (depends on 12)

The transdermal drug delivery system according to claim 12, further comprising a release liner.

### Claim 17 (depends on 1)

A method of manufacturing a composition according to claim 1, comprising forming a polymer matrix comprising a polymer and amphetamine or a pharmaceutically acceptable salt or prodrug thereof, wherein the polymer matrix comprises polyurethane.

### Claim 18 (depends on 1)

A method of manufacturing a composition according to claim 1, comprising providing a polymer matrix comprising a polymer and amphetamine with a backing comprising polyurethane.

### Claim 19 (depends on 19)

The method of claim 19, wherein the backing comprises a polyurethane film layer adjacent the polymer matrix.

### Claim 20 (depends on 17)

A composition for the transdermal delivery of amphetamine made by a method according to claim 17.

### Claim 21 (depends on 18)

A composition for the transdermal delivery of amphetamine made by a method according to claim 18.

### Claim 22 (depends on 1)

A method of transdermally administering amphetamine comprising topically applying to the skin or mucosa of a subject in need thereof a composition according to claim 1.
